SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 368,631.15 |
| Enterprise Value ($M) | 384,402.15 |
| Book Value ($M) | 71,538.00 |
| Book Value / Share | 29.71 |
| Price / Book | 5.15 |
| NCAV ($M) | -54,880.00 |
| NCAV / Share | -22.79 |
| Price / NCAV | -6.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.14 |
| Return on Assets (ROA) | 0.09 |
| Return on Equity (ROE) | 0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.79 |
| Current Ratio | 1.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 53,249.00 |
| Assets | 178,287.00 |
| Liabilities | 108,129.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.53 | -7.07 | |
| 13G/A | State Street Corp | 5.52 | -6.64 | |
| 13G/A | BlackRock, Inc. | 7.70 | -6.28 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,556,718 | 6,499,208 | 23.95 | |
| 1,148,265 | 3,828,127 | 30.00 | |
| 1,353,351 | 5,478,226 | 24.70 | |
| 1,090,134 | 4,954,827 | 22.00 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EBS – Emergent BioSolutions Inc. | ELAN – Elanco Animal Health Incorporated |
| HYAC – Haymaker Acquisition Corp. 4 | LLY – Eli Lilly and Company |
| MRK – Merck & Co., Inc. |